Literature DB >> 8123947

Peripheral intravenous line survival and phlebitis prevention in patients receiving intravenous antibiotics: heparin/hydrocortisone versus in-line filters.

G W Roberts1, M D Holmes, R E Staugas, R A Day, C F Finlay, A Pitcher.   

Abstract

OBJECTIVE: To compare the use of in-line filtration with the addition of heparin/hydrocortisone (hep/hc) to the infusate for both phlebitis prevention and intravenous (i.v.) line survival in peripheral i.v. catheters. This study was specific for a patient group receiving prolonged courses of i.v. antibiotics. Analysis of the two endpoints for conventional short i.v. catheters (short lines) versus long (30 cm) i.v. catheters (long lines) was also performed.
METHODS: Patients with cystic fibrosis receiving intermittent i.v. antibiotics were randomly allocated to receive their drugs either through an in-line filter using a drug-free infusate or with no filter and an infusate containing heparin 500 units and hydrocortisone 10 mg/L. Infusion sites were assessed daily.
RESULTS: Both the hep/hc and filter groups were similar in terms of phlebitis incidence and i.v. line survival when analyzed separately for both short and long lines. Long lines displayed markedly prolonged survival times and reduced phlebitis compared with short lines.
CONCLUSIONS: The effectiveness of i.v. filters in excluding the large particle load introduced by i.v. antibiotics and hence in reducing the subsequent phlebitis makes them a useful alternative to the use of hep/hc. The use of filters in this patient group may offer advantages in terms of ease of use and a possible decrease in hep/hc-related problems. Long lines offer practical advantages over short lines for patients requiring longer term i.v. access.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123947     DOI: 10.1177/106002809402800101

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion.

Authors:  C A Owens; P G Ambrose; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 2.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

3.  Endothelial Cell Toxicity of Vancomycin Infusion Combined with Other Antibiotics.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

Review 5.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

Review 6.  Intravenous in-line filters for preventing morbidity and mortality in neonates.

Authors:  Jann P Foster; Robyn Richards; Marian G Showell; Lisa J Jones
Journal:  Cochrane Database Syst Rev       Date:  2015-08-06

7.  Preventing peripheral intravenous catheter failure by reducing mechanical irritation.

Authors:  Toshiaki Takahashi; Ryoko Murayama; Mari Abe-Doi; Maki Miyahara-Kaneko; Chiho Kanno; Miwa Nakamura; Mariko Mizuno; Chieko Komiyama; Hiromi Sanada
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

Review 8.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis; Amanda Burls
Journal:  Cochrane Database Syst Rev       Date:  2018-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.